BIIB Mar 2023 310.000 call
| Previous close | 4.0000 |
| Open | 4.4000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 310.00 |
| Expiry date | 2023-03-17 |
| Day's range | 4.0000 - 4.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- GlobeNewswire
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of
- Motley Fool
Is Biogen Stock a Buy Now?
Moving new medicines to the market can sometimes make biopharmaceutical companies tons of returns. Biogen (NASDAQ: BIIB) just scored a major new drug approval for an Alzheimer's disease therapy, so investors are understandably rushing to evaluate whether to buy the stock. One key factor that could drive Biogen's outperformance in the next few years is the launch of a new neurology medicine.
- Motley Fool
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.
